INTRODUCTION {#ss1}
============

Southeast Asia has been the source of several emerging zoonotic‐ and vector‐borne disease outbreaks over the years.[^1^](#b1){ref-type="ref"} These include acute encephalitis caused by a novel paramyxovirus, Nipah virus;[^2^](#b2){ref-type="ref"}, [^3^](#b3){ref-type="ref"} hand, foot, and mouth disease (HFMD) caused by coxsackie A16 and enterovirus 71;[^4^](#b4){ref-type="ref"} viral encephalitis and hemorrhagic fevers caused by arboviruses, such as Dengue and Japanese encephalitis viruses;[^5^](#b5){ref-type="ref"} and episodic outbreaks of influenza A virus (H5N1, H9N2, etc.) and acute respiratory syndrome caused by the SARS coronavirus.[^6^](#b6){ref-type="ref"}, [^7^](#b7){ref-type="ref"}, [^8^](#b8){ref-type="ref"}, [^9^](#b9){ref-type="ref"}

A fundamental problem in rapid identification of the etiology of infectious disease outbreaks is the sheer number of microbes, both known and novel, that could potentially be the causative agents. According to a recent review,[^10^](#b10){ref-type="ref"} there are more than 1,400 species of microbes known to be pathogenic to humans. Of these, more than 60% were found to be zoonotic and more than 175 pathogenic species were associated with emerging infectious diseases. These numbers do not include numerous strain variants of each organism or classes of pathogens that infect plants or animals. Further, species variants of an otherwise benign group of microbes may prove infectious to humans and strain‐level genetic changes may confer resistance to antimicrobial agents.

Most of the new technologies being developed for detection of infectious agents incorporate a version of quantitative polymerase chain reaction (PCR), based upon the use of highly specific primers and probes and designed to selectively identify specific pathogenic organisms. Paradoxically, this approach requires assumptions about the type and strain of the infectious agent, limiting detection to a small number of known pathogens. It is both impractical and cost prohibitive to run a large number of individual tests in an attempt to identify every known infectious organism. Moreover, existing tests for known organisms will not identify newly emerging organisms.

Broad‐range PCR methods provide an alternative to single‐agent tests. By amplifying gene targets conserved across groups of organisms, broad‐range PCR has the potential to generate amplification products across entire genera, families, or, as with bacteria, an entire domain of life. This strategy has been successfully employed in the past for bacterial and viral detection.[^11^](#b11){ref-type="ref"}, [^12^](#b12){ref-type="ref"}, [^13^](#b13){ref-type="ref"}, [^14^](#b14){ref-type="ref"}, [^15^](#b15){ref-type="ref"}, [^16^](#b16){ref-type="ref"} The drawback of this approach for epidemiologic applications is that the analysis of PCR products for mixed amplified samples requires sequencing of hundreds of colonies per reaction, and thus it cannot be performed rapidly or cost effectively on large numbers of samples. New approaches to the parallel detection of multiple infectious agents include multiplexed PCR methods[^17^](#b17){ref-type="ref"}, [^18^](#b18){ref-type="ref"} and microarray strategies.[^19^](#b19){ref-type="ref"}, [^20^](#b20){ref-type="ref"}, [^21^](#b21){ref-type="ref"} Microarray strategies are promising because undiscovered organisms might be detected by hybridization to probes designed to conserved regions of known families of bacteria and viruses. However, these methods are not well suited for the high‐throughput detection of a broad spectrum of microorganisms potentially present in complex biological mixtures.

Triangulation identification for genetic evaluation of risks (TIGER) is a universal pathogen detection platform developed under a Defense Advanced Research Projects Agency (DARPA) biodefense program that is capable of identifying an extraordinarily broad range of pathogens ([[fig]{.smallcaps}. 1](#f1){ref-type="fig"}). The process uses electrospray ionization mass spectrometry (ESI‐MS) and base composition analysis of PCR amplification products from highly conserved genomic regions to identify and determine the relative quantity of pathogenic bacteria, viruses, fungi, or protozoa present in a sample. The fundamental distinction between this PCR/ESI‐MS strategy and traditional (specific) nucleic acid tests is the nature of the question being answered. Traditional nucleic acid tests answer the question: "Is infectious organism X in my sample?" The PCR/ESI‐MS method answers the question: "What infectious organisms are in my sample?" In effect, this is equivalent to running many thousands of specific nucleic acid tests because the identity of the infectious organism being detected does not need to be anticipated. The premise of this technology is that it can provide rapid, sensitive, and cost‐effective detection of a broad range of "normal" pathogenic organisms and simultaneously identify unexpected or emerging infectious organisms. This broad function technology may be the only practical way to rapidly diagnose diseases caused by emerging infectious organisms that might otherwise be missed or mistaken for a more common infection.[^22^](#b22){ref-type="ref"} The technology has been validated for a variety of applications, including emerging virus identification,[^23^](#b23){ref-type="ref"} determination of the pathogens involved in acute pneumonia epidemics,[^24^](#b24){ref-type="ref"} and identification of biological weapons agents in a variety of sample types.[^25^](#b25){ref-type="ref"}, [^26^](#b26){ref-type="ref"}

![Automated PCR/ESI‐MS biosensor. Shown in this view are key modules including amplicon purification (desalting), plate stackers, sample injection, and the mass spectrometer. Precise molecular weight determinations of amplicons yield unambiguous base compositions that are used to uniquely "fingerprint" each pathogen. The automated system is capable of analyzing more than 1,500 PCR reactions in 24 h.](NYAS-1102-109-g001){#f1}

The basis of the above approach is the principle that, despite the enormous diversity of microbes, there are sets of essential common features in their biomolecules. Parallel detection of infectious agents takes advantage of highly conserved regions within genes that flank highly variable regions. These conserved genomic features serve as anchors for broad‐range PCR priming to amplify, without prejudice, nucleic acids from most microorganisms in a sample. Such broad‐range PCR reactions targeted across the broadest possible grouping of organisms typically result in a mixture of amplicons, reflecting the complexity of the starting sample. With no further separation, this mixture of PCR amplicons is desalted and analyzed by ESI‐MS for accurate mass measurement, enabling us to determine the base composition (numbers of A, G, C, and T nucleotides) of the PCR amplicons.[^23^](#b23){ref-type="ref"}, [^25^](#b25){ref-type="ref"}, [^26^](#b26){ref-type="ref"} Amplification relies on highly conserved regions, but the variability in sequence between the two primer sites, reflected in the base composition, allows us to distinguish between organisms.

A key aspect of this approach is the concept of "triangulation." In this context, triangulation refers to taking measurements from multiple loci distributed across the microbial genome and using the combination of the measured base composition signatures to identify the organism. While no single PCR target region might give definitive species resolution for all microbes, species can be clearly identified and differentiated from one another using the triangulation strategy across multiple loci. A database of expected base compositions for each primer region for all known organisms was generated using an *in silico* PCR search algorithm (electronic PCR or ePCR). An existing ribonucleic acid (RNA) structure search algorithm has been modified to include PCR parameters, such as hybridization conditions, mismatches, and thermodynamic calculations.[^27^](#b27){ref-type="ref"} This also provides information on primer specificity of the selected primer pairs. The regions are selected so that the nucleic acid composition of the resulting amplicons has sufficient variability to maximally resolve the target organisms. Thus, the measured base compositions from strategically selected locations of the genome are used as a signature to identify and distinguish the organisms present in the original sample.

Detailed experimental protocols have been published elsewhere.[^25^](#b25){ref-type="ref"} Microbes have been identified from human and animal samples (throat swabs, skin wipes, hair, tissue) and from samples obtained from the environment (food products, soil, water, surface wipes, air). Nucleic acids are extracted from bacteria using either a heat or mechanical lysis step. Viral genome isolation is performed using commercially available kits that have been optimized for use in the system. Samples are divided into wells of a microtiter plate that contain pairs of broad‐range PCR primers.

A key element of the PCR/ESI‐MS system is the ability to quantify the levels of genomic material present in the samples. To accomplish this, we include an internal calibrant in each PCR reaction performed. The calibrant consists of a specially designed nucleic acid sequence that is similar to, but distinguishable from, sequences of organisms we might detect. This allows for the simultaneous presence of an accurately quantified amount of a known calibrant deoxyribonucleic acid (DNA) with similar amplification properties to the target sequence during the PCR cycle. Further, this serves as an internal positive control for every PCR reaction. The relative abundances of the end products (as measured by the mass peak heights) can be used in conjunction with the starting concentration of the calibrant to accurately estimate the amount of target sequence in the starting sample ([[fig]{.smallcaps}. 2](#f2){ref-type="fig"}). These measurements are highly reproducible over a wide range of concentrations and provide improved confidence for the determination of the quantity of the infectious agents in the sample.[^24^](#b24){ref-type="ref"}, [^25^](#b25){ref-type="ref"}

![Mass spectra of calibrant and SARS coronavirus (SARS CoV) samples are shown. Both strands were amplified and thus there are two major peaks for both calibrant and SARS. The two templates were observed to be at a relative abundance ratio of approximately 1:1.5. From the input number of calibrant nucleic acid molecules (3 × 10^4^), we estimated that SARS RNA was present in the sample at ∼4.5 × 10^4^ genome copies.](NYAS-1102-109-g002){#f2}

DETECTION AND DISCRIMINATION OF KNOWN AND EMERGING VIRUSES {#ss2}
==========================================================

In this section, we describe two specific applications of the PCR/ESI‐MS method for identifying known and emerging viruses of particular relevance to Southeast Asia. These concepts are equally applicable to bacteria,[^24^](#b24){ref-type="ref"}, [^25^](#b25){ref-type="ref"} other viruses, fungi, and protozoa.

SARS Coronavirus {#ss2-1}
----------------

At the beginning of the SARS outbreak in early 2003, the etiology of the causative agent was not known. Several initial reports based on preliminary characterization of the isolated virus suggested it could be a member of one of several viral families, including *Coronaviridae*. We designed several broad‐range primers targeting the various genera within these families. For broad‐range detection of all coronaviruses, two PCR primer target regions in orf‐1b, one in the RNA‐dependent RNA polymerase (RdRp) and the other in Nsp14, were identified prior to publication of the SARS sequence.[^23^](#b23){ref-type="ref"} Locations of primers within these regions were optimized both for sensitivity and broad‐range priming potential simultaneously by amplifying dilutions of multiple, diverse coronaviruses. *In silico* analysis of the final primer pairs against GenBank nucleotide database sequences showed that these primers would be expected to amplify all coronaviruses but no other viruses, bacteria, or human DNA. [^27^](#b27){ref-type="ref"}

Multiple isolates of a number of different coronavirus species were obtained from various sources (including the American Type Culture Collection \[ATCC\] and the Naval Health Research Center in San Diego). SARS isolates were obtained from the Centers for Disease Control and Prevention (CDC) and from Michael Buchmeier (The Scripps Research Institute, La Jolla, CA). PCR products for all isolates were generated, desalted, and analyzed by ESI‐MS by methods described previously.[^28^](#b28){ref-type="ref"} The spectral signals were algorithmically processed to obtain base compositions of sense and antisense strands of each amplicon.[^29^](#b29){ref-type="ref"} The results from the analysis of 14 coronavirus isolates are shown in [[table]{.smallcaps} 1](#t1){ref-type="table"}. For both target regions, the measured signals agreed with compositions expected from the known coronavirus sequences in GenBank. Several of the isolates used in this study did not have a genome sequence record in GenBank. Nevertheless, we were able to amplify all test viruses and experimentally determine their base compositions. These experimentally determined base compositions were later confirmed by sequencing and deposited in GenBank (AY874541, AY878317‐24). Thus the strategy described here enables identification of organisms without the need for prior knowledge of their sequence.

###### 

**Coronaviruses and their experimentally determined base compositions. Sense and antisense strand masses are shown for each isolate**

  Group             Abbreviation           Source                   Measured masses (Da)   Derived Base compositions   Measured masses (Da)   Derived base compositions
  ----------------- ---------------------- ------------------------ ---------------------- --------------------------- ---------------------- ---------------------------
                    CCoV 1‐71              VR809                    27486.514              A24 G24 C8  T32             42475.955              A33 G31 C19 T54
  26936.574         A32 G8  C24 T24        42185.117                A54 G19 C31 T33                                                           
  CCoV ‐TN449       VR2068                 27471.510                A24 G24 C9  T31        42474.899                   A34 G30 C18 T55        
  26952.548         A31 G9  C24 T24        42184.072                A55 G18 C30 T34                                                           
  FCoV WSU          VR‐989                 27471.517                A24 G24 C9  T31        42490.945                   A33 G31 C18 T55        
  79‐1683                                  26952.556                A31 G9  C24 T24        42169.118                   A55 G18 C31 T33        
  1                 FCoV DF2               VR2004                   27472.497              A23 G25 C10 T30             42450.904              A33 G30 C19 T55
  26953.536         A30 G10 C25 T23        42209.081                A55 G19 C30 T33                                                           
  HCoV 229E         VR740                  27450.532                A25 G24 C11 T28        42462.994                   A36 G30 C20 T51        
  26975.545         A28 G11 C24 T25        42198.061                A51 G20 C30 T36                                                           
  HCoV 229E         NHRC                   27450.506                A25 G24 C11 T28        42462.930                   A36 G30 C20 T51        
  26975.512         A28 G11 C24 T25        42198.040                A51 G20 C30 T36                                                           
                                                                                                                                              
                    BCoV Calf              VR874                    27358.452              A22 G22 C12 T32             42606.039              A38 G32 C15 T52
  Diarrheal virus                          27066.586                A32 G12 C22 T22        42052.897                   A52 G15 C32 T38        
  HCoV OC43         NHRC                   27328.473                A22 G22 C14 T30        42580.959                   A38 G31 C15 T53        
  27098.562         A30 G14 C22 T22        42076.028                A53 G15 C31 T38                                                           
  MHV MHV1          VR261                  27344.491                A21 G23 C14 T30        42602.022                   A37 G34 C18 T48        
  27083.564         A30 G14 C23 T21        42061.016                A48 G18 C34 T37                                                           
  2                 MHV JHM‐thermostable   VR1426                   27344.497              A21 G23 C14 T30             42529.960              A34 G34 C21 T48
  27083.571         A30 G14 C23 T21        42136.047                A48 G21 C34 T34                                                           
  MHV MHV‐          VR764                  27344.503                A21 G23 C14 T30        42599.989                   A34 G35 C18 T50        
  A59                                      27083.572                A30 G14 C23 T21        42064.089                   A50 G18 C35 T34        
  RtCoV 8190        VR1410                 27344.491                A21 G23 C14 T30        42544.967                   A34 G34 C20 T49        
  27083.567         A30 G14 C23 T21        42120.041                A49 G20 C34 T34                                                           
                                                                                                                                              
  3                 IBV Egg‐adapted        VR22                     27396.544              A24 G24 C14 T26             42530.984              A33 G32 C17 T55
  27032.524         A26 G14 C24 T24        42129.100                A55 G17 C32 T33                                                           
                                                                                                                                              
  4                 SCoV TOR2              University of Manitoba   27298.518              A27 G19 C14 T28             42519.906              A34 G33 C20 T50
  27125.542         A28 G14 C19 T27        42144.026                A50 G20 C33 T34                                                           
  SCoV Urbani       CDC                    27298.518                A27 G19 C14 T28        42519.906                   A34 G33 C20 T50        
  27125.542         A28 G14 C19 T27        42144.026                A50 G20 C33 T34                                                           

We further demonstrated the potential to detect multiple viruses in the same sample, as might occur during a co‐infection. Pooled viral extracts from three human coronavirus isolates, HCoV‐229E, HCoV‐OC43, and SARS CoV, were amplified in a mixture and analyzed by PCR/ESI‐MS. Signals from all three viruses were clearly detected and resolved in the mass spectrum demonstrating that co‐infections of more than one coronavirus species could be identified. In addition to broad identification of all coronaviruses tested, including the SARS CoV, we were able to accurately classify the SARS isolates as unrelated but distant members of the group 2 coronaviruses, consistent with the findings of Snijder *et al*.[^30^](#b30){ref-type="ref"} These results are described in detail in Sampath *et al*.[^23^](#b23){ref-type="ref"}

Vector‐Borne Viruses {#ss2-2}
--------------------

Viral encephalitidis is caused by a number of different viruses from different viral families. Important among these are members of the genus *Alphavirus* (*Togaviridae* family) and the genus *Flavivirus* (*Flaviviridae* family); both are single‐strand, positive‐strand RNA viruses. These are major vector‐borne diseases in Southeast Asia and Pacific Rim countries. While the alphaviruses Venezuelan, and eastern and western equine encephalitis viruses (VEEV, EEEV, and WEEV) have received much attention in the Americas for their ability to infect humans and their potential to be used as biowarfare agents, Ross River, Chikungunya, Barmah Forest, and other alphaviruses are common and detrimental to public health in the Asia Pacific regions.[^5^](#b5){ref-type="ref"}, [^31^](#b31){ref-type="ref"}, [^32^](#b32){ref-type="ref"} Genomic changes drive the emergence and reemergence of these viruses as high‐consequence pathogens by causing alterations in host range and virulence properties,[^33^](#b33){ref-type="ref"} and the resulting diversity at the nucleotide and protein levels poses a great challenge for identification and diagnostic strategies. As an example, VEE complex viruses display 13 serologically distinct types belonging to 6 antigenic subtypes (I to VI), and the EEE virus antigenic complex has 4 antigenic subtypes (I--IV), spanning the North and South American isolates.[^34^](#b34){ref-type="ref"}

Our approach for identifying and discriminating these viruses was to design several primer pairs that would amplify all members of the *Alphavirus* genus, and then design primers that amplify distinct regions of the Alphavirus isolates to distinguish subtypes.[^25^](#b25){ref-type="ref"} Broad‐range primer pairs targeting the 5′‐end of the RNA virus genome (nonstructural protein, nsP1 gene) were designed and tested against a number of different viral isolates, including both old world and new world alphaviruses. All of the test isolates showed a perfect match to the expected base compositions where prior data were known, and the tested viral isolates were readily distinguished from one other ([[table]{.smallcaps} 2](#t2){ref-type="table"}). Importantly, the base composition data for some of the isolates represented new measurements from regions that have not been sequenced, showing the potential of this strategy to identify previously unknown or newly emerging viruses. Additional confirmation primer pairs targeting the old and new world alphaviruses have been developed and together they provide complete resolution among all known alphavirus species (Eshoo *et al*., Personal Observation).

###### 

**Alphavirus test isolates and their expected/observed base compositions.^*ab*^**

  Virus             Strain             Sequence available   Expected base composition   Observed base composition
  ------- --------------------------- -------------------- --------------------------- ---------------------------
  VEE       3908 (subtype IC, 1995)           Yes                \[21 23 23 19\]             \[21 23 23 19\]
  VEE      66637 (subtype ID, 1981)           Yes                \[21 23 23 19\]             \[21 23 23 19\]
  VEE      68U201 (subtype IE, 1968)          Yes                \[22 25 19 20\]             \[22 25 19 20\]
  VEE      243937 (subtype IC, 1992)          Yes                \[21 23 23 19\]             \[21 23 23 19\]
  WEE           OR71 (71V1658)                Yes                \[22 26 19 19\]             \[22 26 19 19\]
  WEE           SD83 (R‐43738)                 No                    Unknown                 \[22 26 19 19\]
  WEE           ON41 (McMillan)                No                    Unknown                 \[22 27 18 19\]
  WEE          Fleming (Fleming)               No                    Unknown                 \[22 25 19 20\]
  EEE           (Parker strain)               Yes                \[23 25 19 19\]             \[23 25 19 19\]

  ^*a*^Three of the WEE isolates shown in grey represent *de novo* measurements.

  ^*b*^All isolates were obtained from Dr. Scott Weaver, UTHSC, Galveston, TX.

Influenza Virus Surveillance {#ss2-3}
----------------------------

The biosensor system described here is uniquely suited to influenza virus detection and surveillance in avian, human, or other animal reservoirs. Broad surveillance capability for all influenza viruses is complemented by simultaneous type and subtype level resolution of various identified influenza viruses. This will be useful in monitoring the emergence of new influenza viruses. Based upon the analysis of multiple influenza sequence alignments, pan‐influenza virus PCR primer sets have been developed that are capable of amplifying all three influenza virus species (A, B, and C) and subtypes (HxNy) from different animal hosts (human, avian, swine, etc.) and to distinguish their essential molecular features using base composition signatures (Sampath *et al.*, Personal Observation). To measure the breadth of coverage and resolution offered by this panel we tested 50 different influenza virus isolates, including 22 avian isolates (representing 20 different H/N types, collected from 9 different species of wild birds), 18 human influenza A isolates (8 H1N1, 10 H3N2), 4 swine isolates (including 1 novel type), 1 equine isolate, and 6 human influenza B isolates. The avian influenza samples represented a variety of host species, influenza virus types, geographic locations, and dates of isolation. Despite the diversity of this sample set, the broad‐range primers generated amplicons from all isolates, while the base composition signatures from amplicons obtained with these primers distinguished the isolates (Sampath *et al.*, manuscript submitted). The assay is high throughput (∼300 samples/24 h) and rapid (sample to answer in \<6 h). *In silico* analysis of \>1,400 influenza virus sequences from the GenBank database showed that the primer panel would detect *all known* influenza viruses and distinguish \>90% of all species, with 100% resolution between avian H5N1 and any human isolate. Several hundred human respiratory specimens have been screened using this assay and have shown \>97% sensitivity and specificity of detection compared to traditional characterization.

SUMMARY {#ss3}
=======

TIGER strategy uses a paradigm that allows simultaneous identification of multiple pathogens, including all bacteria, viruses, fungi, and other microorganisms present in a sample without the need for prior knowledge of a specific nucleotide target sequence. Thus previously unanticipated, newly emerging, or potentially unknown organisms can be identified using this platform. The strategy described here uses integrated ESI‐MS and base composition analysis of broad‐range PCR products. Broad‐range PCR reactions are capable of producing products from groups of organisms, rather than single species, and the information content of each PCR reaction is very high. In many cases, including the SARS‐CoV detection described above, priming across broadly conserved regions provides taxonomic resolution at the species level. Where additional subspecies level classification becomes important, broad primers can be supplemented with species‐specific primers that can detect even single nucleotide changes (SNPs) at highly variable loci. As a genotypic method for microbial identification, PCR/ESI‐MS can provide strain‐ or isolate‐level information.[^35^](#b35){ref-type="ref"} These data may be important in epidemiological monitoring to determine the origin of a particular outbreak.

Due to its high throughput capabilities, the methods described will have great utility in a routine survey and detection setting. The mass spectrometer is capable of analyzing complex PCR products at a rate of approximately 1 min per sample. Because the process is performed in an automated, microtiter plate format, large numbers of samples can be examined (\>1,400 PCR reactions/day/instrument), making this process practical for large‐scale analysis of clinical or environmental surveillance samples in public health laboratory settings. This approach can be extended to other viral, bacterial, fungal, or protozoal pathogen groups and is a powerful new paradigm for timely identification of previously unknown organisms that cause disease in humans or animals and for monitoring the progress of epidemics.
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